CL2023000856A1 - Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer - Google Patents

Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer

Info

Publication number
CL2023000856A1
CL2023000856A1 CL2023000856A CL2023000856A CL2023000856A1 CL 2023000856 A1 CL2023000856 A1 CL 2023000856A1 CL 2023000856 A CL2023000856 A CL 2023000856A CL 2023000856 A CL2023000856 A CL 2023000856A CL 2023000856 A1 CL2023000856 A1 CL 2023000856A1
Authority
CL
Chile
Prior art keywords
cancer
pyrrolo
pyridin
treatment
her2
Prior art date
Application number
CL2023000856A
Other languages
English (en)
Inventor
C Milgram Benjamin
D White Ryan
Jr St Jean David
Guzman-Perez Angel
Original Assignee
Scorpion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scorpion Therapeutics Inc filed Critical Scorpion Therapeutics Inc
Publication of CL2023000856A1 publication Critical patent/CL2023000856A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Esta descripción proporciona entidades químicas (por ejemplo, un compuesto o una sal farmacéuticamente aceptable, y/o hidrato, y/o cocristal, y/o combinación de fármacos del compuesto) que inhiben el receptor del factor de crecimiento epidérmico (EGFR, ERBB1) y/o el receptor 2 del factor de crecimiento epidérmico humano (HER2, ERBB2). Estas entidades químicas son útiles, por ejemplo, para tratar una condición, enfermedad o trastorno en el que el aumento (por ejemplo, excesivo) de la activación de EGFR y/o HER2 contribuye a la patología y/o síntomas y/o progresión de la condición, enfermedad o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un ser humano). Esta descripción también proporciona composiciones que las contienen, así como métodos para usar y elaborar las mismas.
CL2023000856A 2020-09-23 2023-03-23 Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer CL2023000856A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063082324P 2020-09-23 2020-09-23
US202063092970P 2020-10-16 2020-10-16

Publications (1)

Publication Number Publication Date
CL2023000856A1 true CL2023000856A1 (es) 2023-11-17

Family

ID=78135207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000856A CL2023000856A1 (es) 2020-09-23 2023-03-23 Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer

Country Status (11)

Country Link
US (1) US20230364070A1 (es)
EP (1) EP4217070A1 (es)
JP (1) JP2023543528A (es)
KR (1) KR20230094197A (es)
AU (1) AU2021347288A1 (es)
CA (1) CA3196712A1 (es)
CL (1) CL2023000856A1 (es)
IL (1) IL301532A (es)
MX (1) MX2023003362A (es)
TW (1) TW202229272A (es)
WO (1) WO2022066734A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023173083A1 (en) * 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2023183601A1 (en) 2022-03-24 2023-09-28 Scorpion Therapeutics, Inc. Methods of synthesizing egfr inhibitors
WO2023205595A2 (en) * 2022-04-20 2023-10-26 Celyn Therapeutics, Inc Egfr inhibitors in cancer treatment

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906194B2 (en) 2003-10-08 2005-06-14 Massachusetts Instititue Of Technology Fluorescence assay for kinase activity
US7964729B2 (en) 2006-08-28 2011-06-21 Massachusetts Institute Of Technology Sox-based kinase sensor
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
WO2013167698A1 (en) 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
CN105209455A (zh) 2013-03-21 2015-12-30 拜耳制药股份公司 3-杂芳基取代的吲唑
EP2976335A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
WO2014176475A2 (en) 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
CN105452242A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
WO2014202583A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
EP3010904A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US9682974B2 (en) 2013-10-30 2017-06-20 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2015175632A1 (en) 2014-05-13 2015-11-19 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
AR100886A1 (es) 2014-06-17 2016-11-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
UA122221C2 (uk) 2015-01-28 2020-10-12 Байєр Фарма Акцієнгезелльшафт 4Н-ПІРОЛО[3,2-c]ПІРИДИН-4-ОНОВІ ПОХІДНІ
EP3310775B1 (en) 2015-06-17 2020-04-01 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107921286A (zh) 2015-08-05 2018-04-17 拜耳制药股份公司 1h‑吡咯‑3‑胺类化合物
KR102075886B1 (ko) 2015-09-01 2020-02-11 다이호야쿠힌고교 가부시키가이샤 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
AU2017363199B2 (en) 2016-11-17 2023-08-17 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
AU2018325442B2 (en) 2017-08-31 2023-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and/or HER2 and methods of use
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2019165385A1 (en) 2018-02-23 2019-08-29 Fulton Group N.A., Inc. Inward-firing premix fuel combustion burner
MX2020008767A (es) 2018-02-23 2021-01-08 Univ Michigan Regents Disruptores del dímero egfr y uso de estos.
CA3096304A1 (en) 2018-06-14 2019-12-19 Dana-Farber Cancer Institute, Inc. Cyano quinoline amide compounds as her2 inhibitors and methods of use
WO2019246541A1 (en) 2018-06-21 2019-12-26 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
WO2020216773A1 (en) * 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
EP3958865A1 (en) * 2019-04-24 2022-03-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
KR20220004103A (ko) * 2019-04-24 2022-01-11 바이엘 악티엔게젤샤프트 4H-피롤로[3,2-c]피리딘-4-온 화합물

Also Published As

Publication number Publication date
AU2021347288A1 (en) 2023-05-04
CA3196712A1 (en) 2022-03-31
US20230364070A1 (en) 2023-11-16
MX2023003362A (es) 2023-05-30
TW202229272A (zh) 2022-08-01
IL301532A (en) 2023-05-01
JP2023543528A (ja) 2023-10-16
EP4217070A1 (en) 2023-08-02
KR20230094197A (ko) 2023-06-27
AU2021347288A9 (en) 2023-07-13
WO2022066734A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
CL2023000856A1 (es) Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer
US20210113711A1 (en) Conjugated biological molecules, pharmaceutical compositions and methods
KR102535283B1 (ko) 암의 치료를 위한 조합 요법
JP2018100303A (ja) 抗腫瘍アルカロイドを用いる、組み合わせの治療法
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
CN109414454A (zh) 用于癌症治疗的组合疗法
RU2013148732A (ru) Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения
US20210093733A1 (en) Conjugated biological molecules, pharmaceutical compositions and methods
ECSP066457A (es) 5-arilpirimidinas como agentes anti-cancer
CR20230185A (es) Compuestos y su uso en el tratamiento del cáncer
CL2023001012A1 (es) Métodos para el tratamiento del cáncer
DOP2023000271A (es) Derivados de la urea que pueden ser utilizados para tratar el cáncer
MX2021002109A (es) Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer.
MX2022013946A (es) Antagonistas del receptor de adenosina a2a.
AR123760A1 (es) Métodos para tratar el cáncer
AR123576A1 (es) Métodos para tratar el cáncer
WO2022133098A3 (en) Compounds and compositions for treating conditions associated with sting activity
WO2022133046A3 (en) Compounds and compositions for treating conditions associated with sting activity
EA201600487A1 (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ СОЛЕВАЯ ФОРМА 3-(1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИН-3-ИЛЭТИНИЛ)-4-МЕТИЛ-N-(4-((4-МЕТИЛПИПЕРАЗИН-1-ИЛ)МЕТИЛ)-3-ТРИФТОРМЕТИЛФЕНИЛ)БЕНЗАМИДА ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ
WO2022072645A3 (en) Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer
WO2022061155A9 (en) Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
UY39342A (es) Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas
AR126753A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
CO2024002311A2 (es) Compuestos y composiciones para tratar condiciones asociadas con actividad de sting
AR126147A1 (es) Derivados de urea para tratar el cáncer